Lung cancer (pulmonary carcinoma) is one of the most common cancers worldwide and the leading cause of cancer-related deaths globally. The diagnostic and therapeutic options for lung cancer have expanded significantly in recent years. Keep reading for latest developments in screening, biomarker testing, treatment innovations, and ongoing research.
A new deep learning model shows promise in detecting and segmenting lung tumors. The findings of the study could have important implications for lung cancer treatment.
A new personalised oncology platform has been tested to detect circulating tumour DNA (ctDNA) in patients with lung adenocarcinoma before surgery, to predict their risk of cancer relapse.
As new research shows, low-dose chest computed tomography (CT) can identify coronary artery calcium, a strong risk factor for coronary artery disease (CAD), in patients without cardiac symptoms.
PET/CT image analysis using artificial intelligence (AI) can predict the occurrence of interstitial lung disease, a serious side effect of immunotherapy in lung cancer, a new study shows.
Researchers from China have developed ultrasensitive, nanoscale sensors that in small-scale tests distinguished a key change in the chemistry of the breath of people with lung cancer.
Kidney cancer is relatively rare, so dedicated screening programmes would not be cost-effective. Combined with lung cancer screening, however, this would be much more feasible, a new study shows.
STAb-T, a new form of immunotherapy to treat solid tumours shows therapeutic potential in animal models with non-small cell lung cancer. The new strategy is designed to strengthen the defensive cells.
Certain long-term health conditions such as chronic obstructive pulmonary disease (COPD) and asthma, can obscure early symptoms of lung cancer, leading to delays in diagnosis, a new study finds.
Cologne researchers have developed an AI-based digital pathology platform to enable extremely fast and accurate fully automated analysis of tissue sections from lung cancer patients.
Artificial Intelligence will be a critical component in ensuring a Europe-wide lung cancer screening programme can achieve its potential, according to speakers at a special ECR 2024 session. Delegates heard that the SOLACE project (Strengthening the screening of Lung Cancer in Europe) will be supported by AI in terms of workflow, diagnostics, and image and data analysis.
Finnish researchers found that using a mobile application based on cognitive behavioral therapy can significantly boost success rates of people attempting to stop smoking.
Lung cancer screenings save lives – especially for those who live in economically deprived areas, a new study confirms. The researchers further demonstrate the benefits of using low-dose CT imaging.
When it comes to lung cancer care, patients in Europe face significant differences depending on the country they are in. Researchers from Amsterdam analysed the landscape.
Under certain circumstances, lung tumours can transform into another, more aggressive cancer type. Now, researchers have found a way to illuminate this process, known as histological transformation.
Using a new technology developed at MIT, diagnosing lung cancer could become as easy as inhaling nanoparticle sensors and then taking a urine test that reveals whether a tumor is present.
Incidence of lung cancer among people who never smoked is rising. A new AI tool opens the door for opportunistic screening for this group, using existing chest X-rays in the electronic medical record.
AI features for automation, integrated systems and more: the role of medical technology has never been as vital as today, and MedTech companies from Taiwan are putting their best foot forward to contribute. At the 2023 Medica trade fair, visitors of the Taiwanese pavilion not only had the opportunity to see the latest medical products on display, but also get acquainted with Taiwanese culture in…
Diagnosing early-stage lung cancer with low-dose CT screening dramatically improves the long-term survival rate of cancer patients, a large-scale, 20-year international study shows.
Cancer has become strikingly more common in people under 50 in the past three decades, an international research team finds. The reseachers explore what this means for future death tolls.
